Andrew M Petros

USPTO Granted Patents = 20 (Patent Applications = 2)

CIPO Patents = 7 (Patent Applications = 2)

EPO Patents = 6 (Patent Applications = 9)

Average Co-Inventor Count = 8.4

ph-index = 15

Forward Citations = 711(Granted Patents)

Location History:

Oakdale, PA (US) (1987)
Mundelein, IL (US) (2004 - 2015)

Company Filing History:

12 out of 4,177

Abbott Laboratories Corporation

The Walter and Eliza Hall Institute of Medical Research

patents

5. 1 out of 1

The Walter and Eliza Hall Medical Research Institute

patent

6. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1987-2015

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9125913 - Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases (2015-09-08),

2. 9072748 - BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases (2015-07-07),

3. 9067928 - Compounds and methods of use (2015-06-30),

4. 8614318 - Apoptosis promoters (2013-12-24),

5. 8586754 - BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases (2013-11-19),

6. 8563735 - Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases (2013-10-22),

7. 8518970 - Compounds and methods of use (2013-08-27),

8. 8354404 - Apoptosis promoters (2013-01-15),

9. 8232273 - Heterocyclic compounds and methods of use (2012-07-31),

10. 8173811 - Apoptosis promoters (2012-05-08),

11. 8114893 - Compounds and methods of use (2012-02-14),

12. 8084607 - Apoptosis promoters (2011-12-27),

13. 7973161 - Apoptosis promoters (2011-07-05),

14. 7767684 - Apoptosis promoters (2010-08-03),

15. 7754886 - N-acylsulfonamide apoptosis promoters (2010-07-13),

Title: Andrew M. Petros: Innovator in Cancer Treatment

Andrew M. Petros is a noteworthy inventor based in Mundelein, IL, with an impressive portfolio of 19 patents to his name. His contributions to the field of medicine, particularly in cancer treatment, have positioned him as a significant figure in the medical research community.

Latest Patents

Among his groundbreaking innovations, Andrew has developed patents focused on Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases. These patents disclose compounds that inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins. The compositions containing these compounds provide methods for treating diseases characterized by the expression of the anti-apoptotic Bcl-2 protein.

Career Highlights

Throughout his career, Andrew has worked with esteemed organizations, including Abbott Laboratories Corporation and AbbVie Inc. His work in these prominent companies has allowed him to contribute to significant advancements in the medical field, particularly regarding novel therapies aimed at improving patient outcomes in cancer treatment.

Collaborations

Andrew has collaborated with notable professionals in his field, including Steven Elmore and Xilu Wang. These collaborations have played a crucial role in the development of his innovative solutions and have helped to enhance the quality of research in the medical community.

Conclusion

In summary, Andrew M. Petros stands out as a dedicated inventor whose work has made meaningful strides in cancer research and treatment. His patents illustrate his commitment to improving health outcomes and his innovative spirit continues to inspire future research endeavors in the field of medicine.

This text is generated by artificial intelligence and may not be accurate.